NCT02755987No Longer Available不适用
Expanded Access to ANG1005 for an Individual Patient With Recurrent WHO Grade III Anaplastic Astrocytoma; Expanded Access to ANG1005 for an Individual Patient With Recurrent WHO Grade III Anaplastic Oligodendroglioma; Expanded Access to ANG1005 for an Individual Breast Cancer Patient With Recurrent Brain Metastases and Leptomeningeal Carcinomatosis.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 试验地点
- 2
研究概览
简要总结
This is an expanded access study with ANG1005 treatment for two individual patients from Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III Anaplastic Oligodendroglioma and one individual patient from Protocol ANG1005-CLN-04 with Recurrent Brain Metastases and Leptomeningeal Carcinomatosis.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Neurologically stable
- •Karnofsky performance status (KPS) ≥ 80
- •Adequate laboratory results
排除标准
- •Radiotherapy within 3 months.
- •Evidence of significant intracranial hemorrhage
- •NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0 Grade ≥ 2 neuropathy
- •Inadequate bone marrow reserve
- •Any evidence of severe or uncontrolled disease
研究者
研究点 (2)
Loading locations...
相似试验
Temporarily Not Available
不适用
Individual Patient Expanded Access to CA102NAdvanced or Metastatic Colorectal Cancer (mCRC)NCT05274204Holy Stone Healthcare Co., Ltd
Unknown
不适用
Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Treatment of SCISpinal Cord Injury at C5-C7 LevelNCT03925649Hope Biosciences LLC
撤回
不适用
SINGLE PATIENT EXPANDED ACCESS OF A PROSPECTIVE, MULTICENTER CLINICAL TRIAL DESIGNED TO EVALUATE THE SAFETY AND PROBABLE BENEFIT OF THE KERAKLEAR NON-PENETRATING KERATOPROSTHESIS IN SUBJECTS WITH CORNEAL OPACITY WITH POOR PROGNOSIS FOR CORNEAL TRANSPLANTCORNEAL OPACITY WITH POOR PROGNOSIS FOR CORNEAL TRANSPLANTNCT03812341University of California, Irvine
No Longer Available
不适用
Individual Patient Expanded Access Gilteritinib (ASP2215)AMLNCT03315299Etan Orgel
No Longer Available
不适用
Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of PembrolizumabNCT04135092National Institutes of Health Clinical Center (CC)